IBRX

Your connection to the $IBRX community.
Following ImmunityBio’s progress across ANKTIVA, clinical development, commercialization, and global expansion.

[IBRX @__IBRX_]

Let’s Save life and the human race. $IBRX

[IBRX @__IBRX_]

Congratulations Gevorg . Your commitment to the underserved and your deep insight to the concern of the next non infectious pandemic of cancer will strengthen the WHO immensely. You have my vote 100percent!!!

[Gevorg Tamamyan @GevTamamyan]

I am honored to announce my candidacy for Director-General of the World Health Organization, nominated by the Republic of Botswana.

I am deeply grateful to President ​Advocate Duma Gideon Boko and the Government of Botswana for their trust.

Botswana has shown the world what determined national leadership can achieve in the face of extraordinary health challenges. I am honored to be nominated by a country with such a powerful story of resilience and progress.

I have spent my career as a pediatric oncologist, building care in places where resources were limited and communities were underserved. I have seen children survive when few believed they would. And I have seen children die simply because of where they were born.

Geography must not decide who lives.

Growing up, the words “recommended by WHO” meant trust. Today, in a world of misinformation and eroding confidence in institutions, we must ensure that the world continues to have WHO—stronger, more agile, and better aligned with today’s realities.

My vision is clear: a World Health Organization that delivers—faster, more effectively, and in true partnership with Member States—so that progress in health reaches every person, everywhere.

It is also an honor to stand alongside such distinguished candidates, each bringing​ important experience and perspectives to this process.

In the months ahead, I look forward to listening to and engaging with Member States across every region of the world.

Dr. Gevorg Tamamyan

@WHO @duma_boko @BWGovernment

[IBRX @__IBRX_]

President @realDonaldTrump can make this happen and change the lives of millions of Americans with cancer. The Cancer Moonshot went nowhere with the past administration but could succeed with President Trump's decisive action today. AMERICAN FIRST.

[IBRX @__IBRX_]

$IBRX Multiply Labs and Dr. Patrick Soon-Shiong are pushing toward fully robotic biotech manufacturing.

[IBRX @__IBRX_]

So exciting to see the results of Anktiva in bladder cancer in women who tend to have higher-grade and more advanced tumors, resulting in a higher risk of recurrence and lower survival rates compared to men.
$IBRX

[IBRX @__IBRX_]

ImmunityBio $IBRX is trading at $9.03 as of 9:37 AM EDT on Sept. 23, down 2.85% from the previous close of $9.29.

Today’s range:$9.00–$9.29
Volume:859,960

A new session,another data point. We’ll keep watching the market action alongside the company’s commercialization progress.

[IBRX @__IBRX_]

@OLovikka Yes!

[IBRX @__IBRX_]

@RiftRover58 @alc2022 $IBRX we are emerging to $11

[IBRX @__IBRX_]

$IBRX is stepping into a new conversation.

Blockchain. Tokenization. Digital ownership.

IBRX Vaults is watching the evolution of biotech and finance as the Nant ecosystem explores what’s next.

The future is moving on-chain. 🔗

#IBRX #IBRXVaults #Blockchain

[IBRX @__IBRX_]

@DrPatrick The future is here. Watch this space as we launch blockchain and tokenized stocks at Nant

[IBRX @__IBRX_]

@SteveHa80206789 Thank you for the support and for helping spread the word about the science. The continued interest in ANKTIVA and the work of the ImmunityBio team is deeply appreciated. 🙏

[IBRX @__IBRX_]

@nssilly_pete Thank you for the support and for helping spread the word about the science. The continued interest in ANKTIVA and the work of the ImmunityBio team is deeply appreciated. 🙏

[IBRX @__IBRX_]

@Kalia3202 Thank you for the support and for helping spread the word about the science. The continued interest in ANKTIVA and the work of the ImmunityBio team is deeply appreciated. 🙏

[IBRX @__IBRX_]

@LT95S Thank you for the support and for helping spread the word about the science. The continued interest in ANKTIVA and the work of the ImmunityBio team is deeply appreciated. 🙏

[IBRX @__IBRX_]

@mark_thrift Appreciate you being here! What’s got your attention most right now the ANKTIVA science, the clinical pipeline, or the $IBRX story?

[IBRX @__IBRX_]

@16Grandkidsrcoo How may I help you?

[IBRX @__IBRX_]

@underwriter63 It does in a lot of ways.

[IBRX @__IBRX_]

@StevoSarduchii2 @DrPatrick @ImmunityBio Thank you.

[IBRX @__IBRX_]

@DrPatrick @ImmunityBio The science continues to drive the conversation.

At #WCLC26, new Phase 3 insights from ReQ201A-NSCLC highlight the importance of immune-cell biology, including ALC and NK cells, in NSCLC.

More research. More data. More to watch. $IBRX #ANKTIVA #WCLC26

[IBRX @__IBRX_]

ANKTIVA’s global footprint keeps expanding. The UAE authorization brought it to 5 regulatory jurisdictions and 34 countries. 🌎 $IBRX
What market do you think will be most interesting to watch next?